Business Wire

MD-PREVAILION

19.10.2020 13:02:07 CEST | Business Wire | Press release

Share
Prevailion Named a 2020 Gartner “Cool Vendor” in Security Operations and Threat Intelligence Field

Prevailion, a global leader in cyber adversary intelligence, today announced that it has been recognized as a Gartner Cool Vendor in the latest Cool Vendors in Security Operations and Threat Intelligence report.

The Gartner report profiles “emerging vendors that security and risk management leaders should consider when evaluating emerging threats requiring the latest in security operations technologies.” Gartner writes that: “Security and risk management leaders are seeking solutions for better visibility into their IT environments to help strengthen their security posture, as well as prioritize security control gaps and remediation activities based on business risk.” It also notes that: “Organizations struggle to mitigate vulnerabilities because of the inability to prioritize them due to a lack of context about the assets and external threat environment.”*

This lack of visibility into active and emerging threats poses a major challenge to organizational cybersecurity, and is the primary focus of Prevailion. Through a global constellation of clandestine sensors, Prevailion actively monitors thousands of cyber attacks in real-time, including billions of malware communications, providing an unprecedented level of adversary intelligence that companies can use to protect their networks.

“We are honored to be selected by Gartner, which we believe validates the core technology behind our platform and the hard work and dedication of our team,” said Karim Hijazi, founder and CEO of Prevailion. “At Prevailion, we have been charting a new course in the field of threat intelligence, by empowering companies with greater visibility into the threat actors targeting their networks and the networks of their closest partners. By going after the attackers’ own infrastructure, we can provide companies with unprecedented insights into criminal and nation-state hackers’ malicious activity and list of targets. This enables corporate security teams to better prioritize threats, by focusing immediately on confirmed attacks, rather than having to rely on noisy and error-prone security alerts or vague risk scorecards.”

EXCLUSIVE INSIGHTS INTO CYBER THREAT ACTIVITY

Prevailion is currently tracking over 28,000 compromised organizations around the world, ranging from publicly traded companies and their supply chain partners to governments, universities, NGOs and more. Many of the cyber compromises Prevailion has observed are undetected or unreported by the victim organizations.

According to Prevailion’s exclusive intelligence, 22% of the Fortune 500 are showing active or recent compromise activity by criminal or state-affiliated hackers. This includes 79% of software companies and 64% of pharmaceuticals, which are the most heavily targeted industries, based on recent cyber activity.

Prevailion’s unique cyber intelligence capability allows it to detect active compromises inside corporate networks that do not require any access or confirmation by the affected corporation. To do this, Prevailion’s intelligence team targets criminal networks in order to intercept communications between the hackers’ “command-and-control” servers and the malware they’ve deployed. This ability to eavesdrop on criminal activity gives Prevailion significantly enhanced insights into real-time hacking operations taking place all over the world. It also allows them to anticipate new attacks ahead of time.

Prevailion’s APEX Platform is a reliable source of information on thousands of unreported corporate breaches, and provides around-the-clock intelligence on new compromises, escalating breach activity and corporate remediation efforts.

*Gartner “Cool Vendors in Security Operations and Threat Intelligence,” Mitchell Schneider, Ruggero Contu, John Watts, Craig Lawson, October 13, 2020.

GARTNER DISCLAIMER

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

ABOUT PREVAILION

Prevailion is a compromise intelligence company, transforming the way organizations approach risk mitigation and business decision-making. Through next-level tailored intelligence and a zero-touch platform, Prevailion provides a full view of confirmed “Evidence of Compromise” (EOC) for customers and their partner ecosystems. To learn more about Prevailion, visit www.prevailion.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye